✨ Free AI Report
Replimune Group, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Replimune Group, Inc.
Company Research

Replimune Group, Inc.: Business Overview, Financials & Competitive Analysis

Replimune is a clinical-stage biotechnology company developing oncolytic immunotherapies to treat cancer by activating the immune system against tumors. Founded in 2015 and headquartered in Woburn, Massachusetts, the ...

Analyst-debate audio for Replimune Group, Inc.

AskCyborg analysts argue the bull and bear cases for Replimune Group, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

Novel oncolytic immunotherapy platform with clinical validation potential, but execution risk and regulatory hurdles typical of...

Read the full analyst-debate transcript →
Industry Biotechnology - Oncology/Immunotherapy
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Replimune Group, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Replimune Group, Inc. Overview

Pro stress-test →

Replimune is a clinical-stage biotechnology company developing oncolytic immunotherapies to treat cancer by activating the immune system against tumors. Founded in 2015 and headquartered in Woburn, Massachusetts, the company has progressed from laboratory research to pending FDA approval status with multiple candidates in clinical development.

Strategic Profile

Pro stress-test →

Replimune's proprietary RPx platform uses a modified HSV-1 backbone designed for dual local and systemic anti-tumor activity, with the ability to combine with established immunotherapies. The company's lead candidate RP1 targets solid tumors, while RP2 and RP3 address immune checkpoint inhibition and T-cell stimulation respectively, positioning the platform for broad oncology applications.

Competitive Landscape

Pro stress-test →

Replimune competes in the oncolytic immunotherapy space against companies developing viral and non-viral approaches. Competitors include Iovance Biotherapeutics (cell-based immunotherapy), Immatics (engineered T-cell therapy), and other checkpoint inhibitor combinations. Replimune's unique dual mechanism and platform approach differentiate it, though competition from established immunotherapy players remains intense.

Industry Context

Replimune Group, Inc. operates in Biotechnology - Oncology/Immunotherapy.

Key facts

Founded: 2015 · Headquarters: Woburn, Massachusetts

What the analysts stress-tested

The top findings that survived the multi-agent debate for Replimune Group, Inc..

  • Lead candidate RP1 approaching potential FDA approval with HSV-1 backbone expressing GM-CSF for multiple solid tumor types
  • Proprietary RPx platform designed for synergy with established cancer treatments and checkpoint inhibitors
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • October 2025RP1 presented at SITC 2025 with late-breaking abstracts on combination with Nivolumab
  • January 2026ISS Governance QualityScore rated 8, indicating strong governance standards
  • +1 moreTrack every material event for Replimune Group, Inc. as it happens. Explore monitoring →
Get alerted when Replimune Group, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Iovance BiotherapeuticsTumor-infiltrating lymphocyte (TIL) cell therapy for solid tumors→Immatics N.V.Engineered T-cell receptor (TCR) therapies for cancer→Syndax PharmaceuticalsEpigenetic and cancer immunotherapy programs→

Compare Replimune Group, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Replimune Group, Inc. operates in Biotechnology - Oncology/Immunotherapy. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Oncology/Immunotherapy research →
NEW · MCP server

Ask your AI assistant about Replimune Group, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Replimune Group, Inc. and its top competitor on Cyborg Score”
“What did Replimune Group, Inc. do this quarter?”
“Is Replimune Group, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Replimune Group, Inc. do?+
Replimune is a clinical-stage biotechnology company developing oncolytic immunotherapies to treat cancer by activating the immune system against tumors. Founded in 2015 and headquartered in Woburn, Massachusetts, the ...
What is Replimune Group, Inc.'s Cyborg Score?+
Replimune Group, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Replimune Group, Inc.'s main competitors?+
Named competitors include Iovance Biotherapeutics, Immatics N.V., Syndax Pharmaceuticals. The full competitive landscape is in the AskCyborg report.
How can I get the full Replimune Group, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Replimune Group, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Replimune Group, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology - Oncology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

5Intensity Therapeutics, Inc.3Alligator Bioscience AB3Elevation Oncology, Inc.7Immatics N.V.